Home » Newsletters » BioWorld Asia

BioWorld Asia

Feb. 14, 2001

View Archived Issues

New Target For Thrombotic Drugs Could Increase Safety

Genset Cuts Back Genomics Focus, Moves On To Discovery

British Biotech's Marimistat Fails In Promising Indication

Oxford Glyco Plans Gaucher NDA On Cerezyme Comparison Study

Despite Resistance In France, Chirac Sees Place For GM Crops

Acambis Achieves Early Results That Validate Flavivirus Vaccine

Curacyte Gets Into Full Swing With US$6.5M Seed Financing

KS Biomedix Moves Lead Drug Into Phase IIb, Eyes Pivotal Trial

Antisoma Planning Financing To Stay Ahead, Keep Flexibility

French Advancing Legislation To Allow Therapeutic Cloning

Hybrigenics, Servier Collaborate On Discovery Of Cancer Drugs

Medica Strengthens Position With Kinase-Targeting Filings

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...